Biodesix announced a new Digital Diagnostics platform integrating blood biomarkers, imaging biomarkers, and AI for lung nodule risk assessment. Developed with Vanderbilt University, the radiomics-based test aims to improve lung cancer risk accuracy and complement existing blood tests. Initial data will be presented in December 2026, with commercial launch expected in 2028. This multimodal approach could expand diagnostics across various lung diseases, leveraging Biodesix's expertise in commercialization and reimbursement.
Biodesix's new Digital Diagnostics platform is the story's subject, providing context for readers. For those following the health sector, 69 of 150 US stocks rose and 42 fell on Pluang today. Notable movers include CYTK at USD 63.50 with a 2.50% increase, HRTX at USD 0.37 up 2.49%, and INO at USD 1.01 rising 2.01%. Data is as of Oct 19, 2026, 15:51 WIB.
The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, at an 8.4% CAGR. This growth is driven by increased R&D investments, rising chronic diseases, and the expansion of biologics, personali...
Starlink Mobile, launched by VEON Ltd. across Ukraine, Kazakhstan, and Bangladesh, has connected over 11 million users in less than a year. The service enables existing 4G phones to access satellite connectivity where terrestrial signals are unavaila...
Medallion Financial Corp. announced it will repurchase $15 million in trust preferred securities from BIMIZCI Fund LLC at 73.66% of face value, costing about $11.05 million plus accrued distributions. This deal includes a five-year standstill agreeme...
Belite Bio, a clinical-stage drug developer focused on retinal diseases, has been approved to move its stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest tier on Nasdaq. This uplisting reflects the company's ...
Heineken N.V. has repurchased a total of 8,865,521 shares under the second tranche of its €1.5 billion share buyback program, spending €629.4 million as of October 16, 2026. This includes shares bought on the exchange and from Heineken Holding N.V. T...
